SCCHNSquamous Cell Carcinoma of the Head and Neck (cancer)
SCCHNSquamous Cell Cancer of the Head and Neck
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The studies on Epithelial Membrane antigen (EMA) in salivary gland function, (89) Enodthelial Cell Markers in Kaposi's sarcoma, (90) Free and acetylated polyamines in SCC and benign oral lesions, (91) Galectins in SCCHN, (92) HCG (human chorionic gonadotropin), (93,94) Heat shock proteins, (95,96,97) in oral SCC and serum ferritin levels in head and neck cancer (98) showed little significant results.
This is the first CHMP positive opinion to recommend a PD-1 inhibitor for this type of treatment for SCCHN. Opdivo is already approved by the EC for six indications in four distinct tumour types.
The Phase 2 part of the trial will enroll 40 patients with HPV16+ recurrent or metastatic SCCHN. Patients will receive the highest TG4001 dose tested in the Phase 1b part of the trial, in combination with avelumab at 10 mg/kg, until disease progression.
- US-based life sciences, diagnostics and chemicals company Agilent Technologies Inc.'s (NYSE: A) Dako PD-L1 IHC 28-8 pharmDx test for squamous cell carcinoma of the head and neck (SCCHN) has been approved for expanded use in Europe, the company said.
This collaboration now involves patients across five tumor types, including metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck (SCCHN).
- The Committee for Medicinal Products for Human Use has recommended the approval of US-based pharmaceutical company Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy, the company said.